ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.723,06
0,22%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,08453
0,19%
Bitcoin
69.704,04
0,87%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Corvus Pharmaceuticals Inc (CRVS)

  7. Corvus Pharmaceuticals Inc (CRVS) News

CRVS

Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CRVS
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202423h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202423h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202423h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202422h01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202422h02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202414h30GlobeNewswire Inc.Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/04/202422h01GlobeNewswire Inc.Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202421h02GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CRVSCorvus Pharmaceuticals Inc
13/03/202421h02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
01/03/202423h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
12/02/202414h30GlobeNewswire Inc.Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202422h27Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202422h05GlobeNewswire Inc.Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/02/202422h05GlobeNewswire Inc.Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerNASDAQ:CRVSCorvus Pharmaceuticals Inc
23/01/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
23/01/202423h00GlobeNewswire Inc.Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/12/202318h00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/12/202322h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/12/202322h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202322h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202322h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202322h01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/11/202314h15GlobeNewswire Inc.Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/11/202300h31GlobeNewswire Inc.Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
31/10/202321h02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023NASDAQ:CRVSCorvus Pharmaceuticals Inc
06/09/202322h05GlobeNewswire Inc.Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDANASDAQ:CRVSCorvus Pharmaceuticals Inc
08/08/202322h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CRVS

Kürzlich von Ihnen besucht

TG
D7G
Nel ASA
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
FX
EURUSD
Euro vs US Dollar
TG
DTE
Deutsche Telekom
TG
DBK
Deutsche Bank
TG
CBK
Commerzbank
TG
NOV
Novo Nordisk
USOTC
BASFY
BASF (QX)
USOTC
BNPQY
BNP Paribas (QX)
FX
EURGBP
Euro vs Sterling
DBI
TDXP
Tec DAX
CCOM
US100
US Tech 100
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten